| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2015: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2013: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Outline of Final Research Achievements |
The mechanism of this study is in vivo engrafted reprogrammed-hepatocyte from adipse tisse derived multilinage progenitor cell, so called ‘ADMPC’ sustained secrete and supplied lysosomal hydrolase deficient in mucopolysaccharidosis to the whole body.Via the portal vein administration of ADMPC, β-galactosidase that are deficient GM1- gangliosidosis mouse, which is a mucopolysaccharidosis model animal had expressed in the blood, and the effect has been revealed that long-lasting. ADMPC have been induced to differentiate into hepatocytes in the liver, so we proposed the new concept of the "in situ reprogramming". The concept is defferent from "Reprogramming", reprogrammed terminal differentiated cell to pluripotent cells and "direct reprogramming", to differentiate directly to the target cells in vitro gene transfer, so far. We are going to deploy this as in situ stem cell therapy to the treatment.
|
